Randomized Controlled: Trial of New Oral Anticoagulants Versus Warfarin for Postcardiac Surgery Atrial Fibrillation

Treatment with rivaroxaban in new-onset atrial fibrillation after cardiac surgery did not decrease length of stay compared with warfarin. However, patients treated with rivaroxaban reported significantly better convenience and a more favorable overall perception of their anticoagulation experience compared with warfarin. Given similar safety profiles, these findings support incorporating rivaroxaban as an option for shared decision-making when selecting anticoagulation therapy for this patient population.

Authors

Institutions

Publication Details

Journal
Annals of Surgery
Published
2025-07-24
DOI
https://doi.org/10.1097/sla.0000000000006853
Citations
1
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Randomized Controlled: Trial of New Oral Anticoagulants Versus Warfarin for Postcardiac Surgery Atrial Fibrillation

David A. D’Alessandro, Arminder S. Jassar, Oluwaseun Akeju, Isabella Turco et al.
1 citations
Annals of Surgery
Atrial Fibrillation Management and Outcomes
1.39
article

Randomized Controlled: Trial of New Oral Anticoagulants Versus Warfarin for Postcardiac Surgery Atrial Fibrillation

David A. D’Alessandro, Arminder S. Jassar, Oluwaseun Akeju, Isabella Turco, Antonia Kreso, Thoralf M. Sundt, Katia M. Colon, Adham Makarem, Jordan P. Bloom, Dane C. Paneitz, Philicia Moonsamy, Breanna R. Ethridge, Selena S. Li, Stanley B. Wolfe, S. Verma, Serguei Melnitchouk, Nathaniel B. Langer, Mauricio A. Villavicencio, Eriberto Michel, Gregory Leya, Yunong Zhao, George Tolis, Asishana A. Osho, S. Rabi
article en
1 citations

Abstract

Treatment with rivaroxaban in new-onset atrial fibrillation after cardiac surgery did not decrease length of stay compared with warfarin. However, patients treated with rivaroxaban reported significantly better convenience and a more favorable overall perception of their anticoagulation experience compared with warfarin. Given similar safety profiles, these findings support incorporating rivaroxaban as an option for shared decision-making when selecting anticoagulation therapy for this patient population.

Annals of SurgeryVol. 282(4)
Massachusetts General Hospital (US)
Good health and well-being
Openalex Percentile: Top 17%
Atrial Fibrillation Management and Outcomes
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.